Abstract | AIM: METHODS: RESULTS: In all patients, serum marker levels decreased to within the normal range by T- ICE. Two patients underwent resection of residual tumor. In one patient, viable cancer cells were detected in resected lymph node tissue and adjuvant chemotherapy was then performed. Although the follow-up period was short (7-15.5 months), four of the five patients (80%) showed no evidence of recurrent disease. No significant differences in side-effects were noted between T- ICE and conventional high dose ICE, which was previously performed in 39 patients at the Division of Urology, Kobe University Graduate School of Medicine, Japan. CONCLUSIONS: High dose chemotherapy, including T- ICE, combined with PBSCT showed an almost identical degree of side-effects as seen in previous high dose chemotherapy without paclitaxel. Although 80% of the patients showed no evidence of disease so far, the efficacy of T- ICE should be evaluated with more patients and longer follow up.
|
Authors | Isao Hara, Yuji Yamada, Masafumi Kumano, Junya Furukawa, Kazuki Yamanaka, Masato Fujisawa |
Journal | International journal of urology : official journal of the Japanese Urological Association
(Int J Urol)
Vol. 12
Issue 12
Pg. 1074-8
(Dec 2005)
ISSN: 0919-8172 [Print] Australia |
PMID | 16409617
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Paclitaxel
|
Topics |
- Adult
- Antineoplastic Agents, Phytogenic
(administration & dosage)
- Combined Modality Therapy
- Feasibility Studies
- Humans
- Male
- Middle Aged
- Neoplasms, Germ Cell and Embryonal
(therapy)
- Paclitaxel
(administration & dosage)
- Peripheral Blood Stem Cell Transplantation
- Testicular Neoplasms
(therapy)
|